# Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)

> **NCT07670546** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **R-Pharm International, LLC** · enrollment: 125 (actual)

## Conditions studied

- Polymyalgia Rheumatica

## Interventions

- **BIOLOGICAL:** Olokizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07670546
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-11
- **Primary completion:** 2026-04-10
- **Final completion:** 2026-07-09
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07670546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07670546, "Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07670546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*